Boston-based drugmaker Vertex, which specializes in rare disorders like cystic fibrosis, doesn’t always attract Big Pharma–level attention. But the firm is on a serious growth trajectory, slated for double-digit expansion in the coming years, per analysts. And the company is branching out into new, brand-name science it hopes can add to its $43 billion market value, including a recent $950 million deal to acquire Semma Therapeutics—a startup that aims to use stem cells to cure Type 1 diabetes.
Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.
Company Information
Overall Score | 2.6 |
Sector | Health Care |
Industry | Biotechnology |
CEO | Jeffrey Leiden |
Website | www.vrtx.com |
HQ Location | Boston |
Country | U.S. |
Revenues ($M) (Past 12 Months) | $3,454 |
Profits ($M) (Past 12 Months) | $2,215 |
Market Value as of Oct. 9, 2019 ($M) | $43,370 |
Employees | 2,500 |